New Hope for Platinum-Resistant Small Cell Lung Cancer: Lurbinectedin Arrives at Jiahui
A novel alkylating agent that targets cancer transcription and reshapes the tumor microenvironment offers a new treatment path for patients with limited options after platinum-based therapy.
SHANGHAI — Jiahui International Cancer Center has officially introduced Lurbinectedin for injection (Zepzelca®), a globally approved novel alkylating antineoplastic agent, for adult patients with metastatic small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based chemotherapy.
Approved by China's National Medical Products Administration (NMPA) in December 2024, lurbinectedin has already received international guideline recommendations. Its arrival at Jiahui marks a meaningful expansion of treatment options for one of the most challenging lung cancer subtypes.
"Lurbinectedin is now officially available at Jiahui International Cancer Center, bringing a new standard-of-care option to Chinese patients facing platinum-resistant or platinum-progressive small cell lung cancer."
The Challenge of Platinum-Resistant SCLC
Small cell lung cancer accounts for approximately 15% of all lung cancers. It is highly aggressive, progresses rapidly, and is frequently diagnosed at advanced stages. For patients whose disease worsens during or after platinum-containing chemotherapy, subsequent treatment options have historically been extremely limited, with poor prognosis and rapid deterioration.
Lurbinectedin's approved indication precisely targets this high-unmet-need population: adults with metastatic SCLC that has progressed on or after platinum chemotherapy.
A Dual Mechanism Against Tumor Growth
Lurbinectedin exerts antitumor activity through a distinctive dual mechanism:
- Selective inhibition of oncogenic transcription: It binds to the DNA minor groove, blocking active transcription and leading to tumor cell apoptosis.
- Modulation of the tumor microenvironment: It reduces tumor-associated macrophages and other supportive cells, weakening the tumor's defense network.
By disrupting both tumor cell proliferation and its surrounding protective environment, lurbinectedin offers a biologically rational treatment path for patients with relapsed or refractory SCLC.
Clinical Efficacy: Meaningful Responses and Manageable Safety
Lurbinectedin demonstrated encouraging efficacy and a controllable safety profile in the pivotal PM1183-B-005-14 trial and the China bridging study LY01017/CT-CHN-101:
| Clinical Endpoint | Result | Clinical Interpretation |
|---|---|---|
| Objective Response Rate (ORR) | 35.2% | More than one-third of patients achieved significant tumor shrinkage |
| Median Overall Survival (mOS) | 9.3 months | Clinically meaningful survival extension in later-line treatment |
| Safety Profile | Manageable | Most common adverse events are myelosuppression, fatigue, and hepatotoxicity, generally manageable with supportive care |
The approval of lurbinectedin signals a new era for SCLC treatment in China — the era of transcription-targeted therapy — offering renewed hope for patients who have exhausted first-line platinum options.
Jiahui oncology team provides personalized consultation and treatment planning for lung cancer patients
Integrated Care at Jiahui International Cancer Center
Jiahui offers more than access to the drug. Patients receive a comprehensive, internationally benchmarked care pathway:
One-Stop Individualized Diagnosis and Treatment
Patients undergo multidisciplinary team (MDT) evaluation at Jiahui's Cancer Center, where medical oncologists, pathologists, radiologists, and clinical pharmacists collaborate to design a personalized treatment plan that may include lurbinectedin.
Full-Course Medication Monitoring
From the first cycle onward, the clinical pharmacy and nursing teams monitor blood counts, liver function, and other safety indicators. Adverse events are identified and managed promptly to protect treatment continuity.
Pharmacy Services and Patient Education
Jiahui's Pharmacy Department supports every step of the treatment journey:
- Drug sourcing and quality assurance: Strict adherence to GSP standards, ensuring reliable supply, compliant storage, and traceable dispensing.
- Clinical rational-use support: Pharmacists participate in MDT discussions, provide dosing recommendations, and perform pre-dispensing prescription review.
- Patient education: One-on-one medication counseling, bedside discharge education, and proactive follow-up for first-time oncology patients to improve adherence and confidence.
Jiahui's multidisciplinary team ensures safe, coordinated care throughout the treatment course
About Jiahui International Cancer Center
Jiahui International Cancer Center is part of Shanghai Jiahui International Hospital and serves as the strategic partner in China of Massachusetts General Hospital (MGH) and its cancer center, a Harvard Medical School-affiliated teaching hospital. Led by internationally experienced oncology specialists, the center provides rapid, guideline-compliant comprehensive cancer services for patients aged 14 and above.
What patients value at Jiahui:
- Internationally benchmarked facilities and clinical capabilities
- Multidisciplinary tumor boards and personalized treatment planning
- Access to globally approved oncology agents, including novel therapies
- Multilingual communication support for international patients
- Private, comfortable treatment environment
- Continuous clinical pharmacy and nursing monitoring
Considering Lurbinectedin for SCLC?
Contact our international patient team to arrange a remote consultation with Jiahui oncology specialists. We can review your medical history, discuss eligibility, and coordinate treatment planning.
Request a ConsultationDisclaimer: This article is based on publicly available clinical data and regulatory announcements. It does not constitute medical advice. Eligibility for lurbinectedin treatment must be determined by a qualified oncologist based on the patient's diagnosis, prior treatment history, and overall health status. Please consult a medical professional for personalized treatment recommendations.
References:
[1] Chinese Society of Clinical Oncology (CSCO). Guidelines for Small Cell Lung Cancer Diagnosis and Treatment (2025).
[2] NCCN. Small Cell Lung Cancer. Version 4.2025.
[3] Dingemans AC, et al. Ann Oncol. 2021;32(7):839-853.